ATE362483T1 - Universeller träger zum zielrichten von molekülen zu rezeptor gb3 - exprimierenden zellen - Google Patents

Universeller träger zum zielrichten von molekülen zu rezeptor gb3 - exprimierenden zellen

Info

Publication number
ATE362483T1
ATE362483T1 AT02700240T AT02700240T ATE362483T1 AT E362483 T1 ATE362483 T1 AT E362483T1 AT 02700240 T AT02700240 T AT 02700240T AT 02700240 T AT02700240 T AT 02700240T AT E362483 T1 ATE362483 T1 AT E362483T1
Authority
AT
Austria
Prior art keywords
expressing cells
receptor
targeting molecules
universal carrier
cys
Prior art date
Application number
AT02700240T
Other languages
English (en)
Inventor
Ludger Johannes
Eric Tartour
Bruno Goud
Wolf Fridman
Original Assignee
Inst Curie
Centre Nat Rech Scient
Inst Nat Sante Rech Med
Univ Paris Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Curie, Centre Nat Rech Scient, Inst Nat Sante Rech Med, Univ Paris Curie filed Critical Inst Curie
Application granted granted Critical
Publication of ATE362483T1 publication Critical patent/ATE362483T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02700240T 2001-02-01 2002-02-01 Universeller träger zum zielrichten von molekülen zu rezeptor gb3 - exprimierenden zellen ATE362483T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01400255A EP1229045A1 (de) 2001-02-01 2001-02-01 Universeller Träger zum Zielrichten von Molekülen zu Rezeptor Gb3 - exprimierenden Zellen

Publications (1)

Publication Number Publication Date
ATE362483T1 true ATE362483T1 (de) 2007-06-15

Family

ID=8182611

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02700240T ATE362483T1 (de) 2001-02-01 2002-02-01 Universeller träger zum zielrichten von molekülen zu rezeptor gb3 - exprimierenden zellen

Country Status (11)

Country Link
US (3) US7632514B2 (de)
EP (2) EP1229045A1 (de)
JP (1) JP4296536B2 (de)
AT (1) ATE362483T1 (de)
CA (1) CA2435712C (de)
CY (1) CY1106789T1 (de)
DE (1) DE60220136T2 (de)
DK (1) DK1355928T3 (de)
ES (1) ES2287239T3 (de)
PT (1) PT1355928E (de)
WO (1) WO2002060937A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229045A1 (de) 2001-02-01 2002-08-07 Institut Curie Universeller Träger zum Zielrichten von Molekülen zu Rezeptor Gb3 - exprimierenden Zellen
ATE292144T1 (de) * 2002-08-02 2005-04-15 Inst Curie Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren
GB0411411D0 (en) * 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP1938836A1 (de) * 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Verbindungen mit Shigatoxin-B-Untereinheit und Mittel zur Stimulation von NKT-Zellen
GB0724360D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
GB0724357D0 (en) * 2007-12-14 2008-01-23 Glaxosmithkline Biolog Sa Method for preparing protein conjugates
US20090214438A1 (en) * 2007-12-18 2009-08-27 Institut Curie Methods and compositions for the preparation and use of toxin conjugates
EP2072060A1 (de) 2007-12-18 2009-06-24 Institut Curie Verfahren und Zusammensetzungen zur Herstellung und Verwendung von Toxinkonjugaten
EP2548571A1 (de) 2011-07-22 2013-01-23 Institut Curie Zusammensetzungen mit Mitteln zum Targeting von mindestens einem Antigen zu dendritischen Zellen
EP2740491A1 (de) * 2012-12-05 2014-06-11 Institut Curie Konjugate der B-Untereinheit von Shiga-Toxin zur Verwendung als Kontrastmittel zur Bildgebung und Therapie
EP2740493A1 (de) 2012-12-05 2014-06-11 Institut Curie Konjugate der B-Untereinheit von Shiga-Toxin für Antikrebstherapien
EP3058956A1 (de) 2015-02-23 2016-08-24 Institut Curie Kombinierte Impfungs-/Strahlentherapie zur Krebsbehandlung
EP3612552A1 (de) 2017-04-20 2020-02-26 Institut National de la Santé Et de la Recherche Médicale Peptide, insbesondere polypeptide, phagenanzeige-screening-verfahren und assoziierte mittel und deren verwendungen für forschungs- und biomedizinanwendungen
US20220233673A1 (en) 2019-06-04 2022-07-28 Institut Curie METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STxB) MONOMERS AND OLIGOMERS, AND USES THEREOF
WO2022117764A1 (en) * 2020-12-02 2022-06-09 Institut Curie FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF
CN113754733B (zh) * 2021-09-18 2023-10-20 上海交通大学 一种vGPCR蛋白靶向肽的筛选方法及其嵌合毒素与应用
CN116236584B (zh) * 2023-02-20 2024-03-22 四川大学 一种用于高效递送siRNA的多糖-多肽偶联物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
WO1995011998A1 (en) * 1993-10-26 1995-05-04 United Biomedical, Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
DE4430601A1 (de) * 1994-08-22 1996-02-29 Beiersdorf Ag Zelladhäsions-Peptide zur Modifikation des Haftungsverhaltens eukaryontischer Zellen untereinander
JPH11506424A (ja) * 1995-03-24 1999-06-08 オフィディアン ファーマシューティカルズ インコーポレーテッド ベロ毒素産生大腸菌に対する治療
DE19603649A1 (de) * 1996-02-01 1997-08-07 Werner Lubitz Rekombinante Expression von S-Layer-Proteinen
FR2766193B1 (fr) * 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
GB9808932D0 (en) * 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP1229045A1 (de) * 2001-02-01 2002-08-07 Institut Curie Universeller Träger zum Zielrichten von Molekülen zu Rezeptor Gb3 - exprimierenden Zellen
ATE292144T1 (de) * 2002-08-02 2005-04-15 Inst Curie Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren
MX2007014390A (es) * 2005-05-19 2008-02-12 Glaxosmithkline Biolog Sa Composicion de vacuna que comprende subunidad b de termo toxina e. coli y antigeno y adyuvante.
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
ES2532985T3 (es) * 2006-02-16 2015-04-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Proteínas quiméricas de toxoide de Shiga
WO2007124133A2 (en) * 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on shiga toxin type 1 protein
EP2517723B1 (de) * 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Zusammensetzungen und Verfahren zur Verstärkung von Immunreaktionen
EP1938836A1 (de) * 2006-12-28 2008-07-02 Universite Rene Descartes (Paris V) Verbindungen mit Shigatoxin-B-Untereinheit und Mittel zur Stimulation von NKT-Zellen
AU2007339753A1 (en) * 2006-12-29 2008-07-10 Osprey Pharmaceuticals Usa, Inc. Methods of selecting and producing modified toxins, conjugates containing modified toxins and uses thereof
EP2145873A1 (de) * 2008-06-17 2010-01-20 Commissariat A L'energie Atomique Neue Verbindungen, die eine Schutzaktivität gegen die Wirkung von Toxinen und Viren über einen intrazellulären Wirkungsmechanismus entfalten
PE20120425A1 (es) * 2009-01-23 2012-05-03 Jackson H M Found Military Med Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga
KR101967205B1 (ko) 2011-10-14 2019-04-09 3디티엘, 인코퍼레이티드 적어도 하나의 동적 효과 특징을 포함하는 보안 특징을 갖는 보안 요소 또는 문서

Also Published As

Publication number Publication date
US7632514B2 (en) 2009-12-15
CA2435712C (en) 2012-07-10
US9603923B2 (en) 2017-03-28
US20150045536A1 (en) 2015-02-12
JP4296536B2 (ja) 2009-07-15
PT1355928E (pt) 2007-08-23
EP1355928B1 (de) 2007-05-16
US20040110935A1 (en) 2004-06-10
DK1355928T3 (da) 2007-09-24
EP1355928A1 (de) 2003-10-29
ES2287239T3 (es) 2007-12-16
WO2002060937A1 (en) 2002-08-08
CY1106789T1 (el) 2012-05-23
EP1229045A1 (de) 2002-08-07
US8852612B2 (en) 2014-10-07
DE60220136D1 (de) 2007-06-28
JP2004531230A (ja) 2004-10-14
CA2435712A1 (en) 2002-08-08
DE60220136T2 (de) 2008-01-24
US20100196418A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
DE60220136D1 (de) Universeller träger zum zielrichten von molekülen zu rezeptor gb3 - exprimierenden zellen
ATE369878T1 (de) Träger-pharmaka-konjugate
Bursavich et al. From peptides to non-peptide peptidomimetics: design and synthesis of new piperidine inhibitors of aspartic peptidases
BR0011849A (pt) Anticorpos enxertados lm609 melhorados
BR0211926A (pt) agentes para realçar a resposta imune
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
DK1360203T3 (da) Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
DK1053355T3 (da) PNA- og DNA-konjugater og metoder til fremstilling heraf
ATE459004T1 (de) Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung
EP1555325A4 (de) Neue fructosylpeptidoxidase und deren nutzung
DK1111385T3 (da) Enzym-protein-kompleks
DE60313659D1 (de) Borrelidin-derivate und ihre medizinische anwendung
DE69433015D1 (de) Neue Enzyme und Prodrugs für ADEPT
DE69814735D1 (de) Carbazolcarboxamide als 5-HT1F Agonisten
BR0213779A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
BRPI0409736A (pt) anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados
DE60203491D1 (de) Shiga-Toxin-Untereinheit B als Vektor zur Diagnose von Tumoren und zur Arzneimittelverabreichung an GB3-exprimierenden Tumoren
EA200300246A1 (ru) Ген и белок, ассоциированные с шизофренией
FR2797689B1 (fr) Utilisation de composes synthetiques pour des immunodosages
DE69929454D1 (de) Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
DK1137442T3 (da) Biologisk aktive konjugater havende en detekterbar rapportermoietet og fremgangsmåde til identificering af nævnte derivat
DE69939986D1 (de) Transkriptionsfaktor für mhc klasse ii gene sowie dessen hemmer und deren medizinische anwendung
DE69900283D1 (de) Reninaktive Substanz enthaltend humanes Prorenin und Antikörper gegen das Prorenin Profragment
DE60031856D1 (de) Säugeradhäsionprotease
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1355928

Country of ref document: EP